Chemotherapy-Induced Hair Loss in Sarcoma Patients

Standard Therapies and Hair Loss Risk

The European Society for Medical Oncology recommends first-line therapy for soft tissue sarcomas based on anthracyclines, specifically doxorubicin, which regularly leads to severe hair loss 1, 2
For osteosarcomas and Ewing's sarcomas, combination therapies with doxorubicin, ifosfamide, cyclophosphamide, vincristine, dactinomycin, and etoposide are used, also associated with a high risk of alopecia 3
The combination of doxorubicin with ifosfamide can lead to higher response rates in certain sarcoma types but increases the risk of hair loss 4, 5

Taxanes can be considered as an alternative to anthracyclines for angiosarcomas, although they also frequently lead to hair loss 4, 5
Trabectedin as a second-line option after anthracyclines has proven effective in certain sarcoma types (especially leiomyosarcoma and liposarcoma) and less often causes severe alopecia 4, 5

For high-risk sarcomas with curative intent, standard chemotherapy regimens with anthracyclines should be used, combined with scalp cooling to minimize hair loss 1
As a second-line therapy, trabectedin should be considered for suitable histological subtypes 4, 2
For angiosarcomas, taxanes can be considered as an alternative to anthracyclines 4, 5

The decision to use a less effective chemotherapy to avoid hair loss must be carefully weighed against potential survival disadvantages 1, 4
The cumulative dose of doxorubicin should be monitored to minimize cardiotoxic effects 2
Treatment should be performed in specialized sarcoma centers with experience in treating these rare tumors 2